Watch for any superior proposals during the 30-day go-shop period ending late October 2026. The CVR milestones target significant revenue growth (non-Alcon revenue from ~$120M in 2028 to $175M in 2029) and $120M EBITDA by 2030, monitor quarterly performance against these thresholds. Stockholder vote and HSR clearance are key near-term catalysts.
Price Chart
Executive Summary
Lifecore Biomedical entered into a definitive merger agreement to be acquired by an affiliate of Webster Equity Partners for $6.28 per share in cash plus one contingent value right (CVR) per share. The CVRs provide potential additional payments of up to $160 million in aggregate based on achieving revenue and EBITDA milestones through 2030. The transaction is supported by voting agreements with Wynnefield Capital and Legion Partners stockholders representing significant ownership, and the company has a 30-day go-shop period to solicit superior proposals.
Key Financial Metrics
Key Facts
- Merger consideration: $6.28 per share in cash plus one CVR per share
- CVR milestones: up to $30M (2028), $45M (2029), $85M (2030) = $160M aggregate potential
- Equity financing of $400M from Webster affiliates, plus $115M term loans, $30M revolver, and $35M Alcon term loan
- Go-shop period of 30 days; termination fees: $7.47M (go-shop), $9.96M (company), $16.18M (reverse)
- Voting agreements cover Wynnefield Capital and Legion Partners stockholders
- Closing conditions include stockholder approval, HSR clearance, and Alcon agreements remaining in effect
- Initial termination date: June 27, 2027, extendable to September 27, 2027
Financial Impact
Total enterprise value approximately $238M based on 37.9M shares outstanding at $6.28/share, plus up to $160M in CVR payments
Risk Factors
- Stockholder approval not guaranteed despite voting agreements
- CVR payments are contingent on aggressive revenue and EBITDA targets
- Alcon agreements must remain in effect, any disruption could block the deal
- Regulatory approvals (HSR) may delay or prevent closing
- Go-shop period could result in a superior proposal triggering termination fee
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-037768 |
| Document: 0001140361-26-037768-index-headers.html | 0001140361-26-037768 |
| Document: 0001140361-26-037768-index.html | 0001140361-26-037768 |
| Document: 0001140361-26-037768.txt | 0001140361-26-037768 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 9d ago | 8-K | $6.37 $6.37 | · 0.00% | ▲ +1.18% | $6.52 (+2.35%) |
Sep 28, 2026 4w ago | SC 13D/A | $6.59 $6.58 | ▼ −0.15% | ▲ +0.05% | $6.52 (−1.06%) |
Sep 28, 2026 4w ago | DEFA14A | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.52 (−0.00%) |
Sep 28, 2026 4w ago | 8-K | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.52 (−0.00%) |
Sep 28, 2026 4w ago | Press Release | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.52 (−0.00%) |
Aug 5, 2026 12w ago | 8-K | $4.44 $4.84 | ▲ +9.01% | ▲ +9.17% | $6.52 (+46.85%) |
Jul 2, 2026 17w ago | 8-K | $5.09 $5.05 | ▲ +0.79% | ▲ +1.66% | $6.52 (−28.09%) |
Jun 15, 2026 19w ago | Press Release | $5.49 $5.35 | ▼ −2.55% | ▼ −1.95% | $6.52 (+18.76%) |
Jun 5, 2026 20w ago | 8-K | $5.57 $5.66 | ▲ +1.62% | ▲ +1.91% | $6.52 (+17.06%) |
Jun 2, 2026 21w ago | Press Release | $5.45 $5.67 | ▲ +4.04% | ▲ +4.73% | $6.52 (+19.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers